XenoPort

Shares of XenoPort, Inc. (NASDAQ: XNPT) were trading higher by nearly 6 percent at $5.07 early Friday morning. Reuters reported late Thursday afternoon that the bio-pharmaceutical company is in the early stages of exploring a potential sale of itself. Citing "people familiar with the...

Piper Jaffray is out with its report today on XenoPort (NASDAQ: XNPT), reiterating Overweight. In a note to clients, Piper Jaffray writes, "Yesterday, Xenoport announced that a Phase III study for XP19986, in multiple sclerosis patients with spasticity will be run under a Special Protocol...

Wedbush is reiterating its OP rating and $23 PT on shares of XenoPort, Inc. (NASDAQ: XNPT). XenoPort closed Wednesday at $6.38. “Our price target of $23/share is derived from a sum of the parts valuation,” Wedbush writes. “We do not include the potential for ex-U.S. royalties for any products,...

Deutsche Bank is out with its report on XenoPort (NASDAQ: XNPT), upgrading shares of XNPT to Buy. In a note to clients, Deutsche Bank writes, "XenoPort and partner GSK announced late Wednesday that the FDA approved Horizant for treatment of moderate to severe Restless Legs Syndrome in adults. We...

Deutsche Bank has upgraded XenoPort (NASDAQ: XNPT) from Hold to Buy and has raised the price target from $6 to $13.

Lazard Capital Markets has upgraded XenoPort (NASDAQ: XNPT) from Sell to Hold.

Shares of XenoPort, Inc. (Nasdaq: XNPT) crashed today after the pharmaceutical company received word from the FDA that it would not approve the company's development stage drug called Horizant, which XenoPort developed with partner GlaxoSmithKline Plc (NYSE: GSK). The FDA said that pancreatic tumor...

Shares of pharmaceutical company Depomed, Inc. (Nasdaq: DEPO) fell today, amid FDA concerns and an analyst downgrade. The bad news began when fellow drugmaker XenoPort, Inc. (Nasdaq: XNPT) received a letter from the FDA stating that the company would not approve its gabapentin encarbil drug called...